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Abstract
Objective: Prediction of the survival time for patients with hepatocellular 
carcinoma (HCC) by a clinical staging system could influence treatment 
planning. The aim of this study was to evaluate the predictive power of the 
Cancer of the Liver Italian Program (CLIP) and the Okuda staging system 
in the prognosis of patients with HCC in eastern Taiwan.
Materials and Methods: We performed a retrospective chart review of 
patients admitted from 1986 to 2000 with a diagnosis of HCC. Parameters 
for staging with the Okuda and CLIP systems were collected. The median 
survival time and 5-year survival curves were obtained using the Kaplan-Meier 
method. The discriminatory ability of the systems was also compared.
Results: A total of 342 cases were included in the study. The median sur-
vival time of patients at Okuda stage I (24.3% of patients), II (56.1%) and 
III (19.6%) was 16.8, 5.0 and 1.9 months, respectively. The respective 5-year 
survival rates were 19.0%, 5% and 0%. The median survival times of patients 
with CLIP scores of 0 (10.2% of patients), 1 (16.1%), 2 (23.1%), 3 (24.9%), 4 
(15.2%), 5 (7.9%) and 6 (2.6%) were 32.7, 10.3, 6.7, 4.7, 2.5, 1.9 and 0.8 
months, respectively. The respective 5-year survival rates were 23%, 14%, 
10%, 1.1%, 0%, 0% and 0%. The CLIP classification showed more promi-
nent discriminatory ability than the Okuda classification, as confirmed by 
statistical methods.
Conclusion: The CLIP system is more accurate in identifying patients at 
both extremes of better and worse prognoses than the Okuda classifica-
tion, and can be used to stratify patients for prospective therapeutic trials 
for HCC in eastern Taiwan. [Tzu Chi Med J 2009;21(1):34–39]
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1. Introduction
Hepatocellular carcinoma (HCC) is the most common 
cause of cancer death in Taiwan [1]. The global annual 
incidence and mortality are around half a million, mak-
ing HCC the fifth most common human malignancy 
[2]. In clinical practice, patients with HCC have a poor 
prognosis despite recent advances in diagnosis and 
treatment [3]. Small lesions found in cancer screening 
programs are usually asymptomatic and can be treated 
with surgical resection, transplantation [3] or local 
ablation procedures [4,5]. However, HCC may invade 
hepatic blood vessels at relatively early stages, and the 
accompanying cirrhosis may compromise liver func-
tion and limit the safety of treatment procedures [6,7]. 
Thus the prognosis of patients with HCC is determined 
not only by tumor morphology, but also by vascular 
invasion and liver functional reserve.
An estimate of prognosis during the diagnosis pe-
riod is important in the planning of treatment. An ideal 
staging system for estimation of prognosis should be 
simple, accurate, reproducible and inexpensive to im-
plement, and should use objective parameters. The 
Okuda staging system for HCC has been used for many 
years [8], but factors like vascular invasion, and α-
fetoprotein (AFP) levels are not considered, and new 
systems are therefore emerging [9–13]. Some systems 
which use parameters such as performance status 
are inaccurate and difficult to assess in retrospective 
studies because of interpersonal variation. After re-
viewing several recently developed prognosis indicator 
systems in the literature, the Cancer of the Liver Italian 
Program (CLIP) classification system [9] seemed to be 
most commonly used and suitable for a retrospective 
cohort.
HCC is a cancer with high mortality in eastern Taiwan 
[1]. The lack of reference data from a prognostic 
predictive system in this area makes clinical decisions 
for suitable treatment difficult. In this retrospective 
study, we analyzed our patients to validate the predic-
tive value of the CLIP classification, and compared its 
discrimination power with that of the Okuda staging 
system.
2. Materials and methods
A computer search was done of the hospital records 
of inpatients who had been admitted with a main diag-
nosis of HCC from 1986 to 2000. A total of 493 cases 
were identified. Data collected included patient’s age, 
sex, ethnic origin, social habits, laboratory results, di-
agnostic methods, hepatitis markers, imaging studies, 
treatment modalities, and outcome. The CLIP and 
Okuda classification variables are defined in Table 1. 
Patients who died during their first admission were also 
included. Patients with incomplete data for the CLIP 
(79 cases) and Okuda staging systems (72 cases) 
were excluded.
Survival status was queried by telephone contact 
with family members of the patients. Status was fur-
ther verified using the National Death Certificate data-
base, using national identification number, gender and 
birth date as linking variables. The date of December 
31, 2001 was defined as the last census date in this 
study.
A total of 342 cases with complete data were in-
cluded in the analysis. Median survival time and 5-year 
survival curves were obtained by the Kaplan-Meier 
method. The log-rank test was used to compare the 
survival rates of patients with different staging scores. 
Cox’s proportional hazards regression was used to 
analyze the effect of both staging systems on the sur-
vival prediction. The likelihood ratio χ2 test derived 
Table 1 — Parameters of the CLIP and Okuda staging systems
Variables CLIP system Score Okuda system Score
Tumor morphology Single nodule and ≤ 50% liver volume 0 ≤ 50% liver volume 0
 Multiple nodules and ≤ 50% liver volume 1 > 50% liver volume 1
 Massive or > 50% liver volume 2
Portal vein thrombosis No 0
 Yes 1
AFP ≤ 400 ng/mL 0
 > 400 ng/mL 1
Child-Pugh class A 0
 B 1
 C 2
Ascites   No 0
   Yes 1
Albumin   > 3.0 g/dL 0
   ≤ 3.0 g/dL 1
Bilirubin   ≤ 3 mg/dL 0
   > 3 mg/dL 1
CLIP = Cancer of the Liver Italian Program; AFP = α-fetoprotein. Okuda stage I = 0 points; II = 1–2 points; III = 3–4 points.
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from analysis of the Cox regression model was used 
to determine the homogeneity (small differences in 
survival among cases in the same group of each sys-
tem) [14]. The linear trend χ2 test was used to measure 
the discriminatory ability of each staging system [15] 
and Akaike’s information criterion was used to de-
termine which was the more explanatory-informative 
system [16].
All statistical analyses were performed using SAS 
version 8.2 (SAS Institute Inc., Cary, NC, USA) for Win-
dows, SPSS version 12 (SPSS Inc., Chicago, IL, USA) 
for Windows, and MedCalc version 9.3.7.0 (MedCalc 
Software, Mariakerke, Belgium) for Windows.
3. Results
The diagnosis of HCC was made by pathologic exami-
nations in 17.2% of patients and by typical imaging 
findings, in addition to elevated AFP and clinical course 
in 82.8%. The clinical characteristics of 342 patients at 
diagnosis are described in Table 2. The median age 
at diagnosis was 47.6 years. The majority of patients 
were male. More than 60% of patients were HBsAg-
seropositive, while around one third of patients were 
anti-HCV-seropositive. Most patients had accompany-
ing liver cirrhosis. Our patients tended to present late 
in the course because more than half (53.5%) received 
no treatment.
The statistical analysis of patients according to the 
CLIP and Okuda prognostic systems for HCC and the 
Child-Pugh classification for liver cirrhosis (assessment 
of residual liver function) are shown in Table 3. The 
CLIP system delimits more subsets of patients with 
statistically significant differences in median survival 
times and survival rates than the Okuda system. The 
5-year survival curves were plotted using the Kaplan-
Meier method according to the CLIP (Fig. 1) or Okuda 
(Fig. 2) classifications.
To increase the discriminatory ability of the CLIP 
system, we merged cases with CLIP scores of 4, 5 and 
6 in the same group for further statistical analysis. 
Cox’s proportional hazards regression showed good 
survival prediction for both the CLIP and Okuda clas-
sifications (Table 4, Figs. 3 and 4). The CLIP staging 
system showed higher linear trends and homogeneity 
likelihood ratio χ2 values and lower Akaike’s informa-
tion criterion value, confirming that the CLIP classifi-
cation is statistically better than the Okuda system 
(Table 5).
4. Discussion
HCC is prevalent in Asians because of the high prev-
alence of viral hepatitis [2,3]. It is the most common 
cause of cancer death in Taiwan [1]. In reviewing the 
clinical prognostic predicting systems in the literature, 
we found that the CLIP system seemed to be optimal. 
Similar results were confirmed for patients with HCC 
in eastern Taiwan. Assessment is easy in the CLIP sys-
tem and it can be used to stratify patients into groups 
with identical scores to compare different treatment 
modalities in prospective studies.
In the past, the principal prognostic systems for HCC 
were the TNM (tumor, node, metastasis) and the Okuda 
systems, but limitations and criticisms have emerged, 
mainly related to the incomplete assessment of re-
sidual liver function and the lack of many prognostic 
Table 2 — Clinical characteristics of 342 patients on 
admission
 n (%)
Sex 
 Female 60 (17.5)
 Male 282 (82.5)
Age at diagnosis (yr) 
 < 60 152 (44.4)
 ≥ 60 190 (55.6)
Ethnicity 
 Han Chinese 222 (71.4)
 Taiwanese Aborigines 29 (9.3)
 Unknown 60 (19.3)
HBsAg serostatus 
 Negative 129 (37.7)
 Positive 206 (60.2)
 Unknown 7 (2.0)
Anti-HCV serostatus 
 Negative 201 (58.8)
 Positive 93 (27.2)
 Unknown 48 (14.0)
α-fetoprotein 
 0–12.5 76 (22.2)
 12.6–400 98 (28.7)
 > 400 168 (49.1)
Cirrhosis 
 No 58 (17.0)
 Yes 284 (83.0)
Child-Pugh score 
 A 144 (42.1)
 B 139 (40.6)
 C 59 (17.3)
Ascites 
 No 228 (66.7)
 Mild 63 (18.4)
 Moderate or severe 51 (14.9)
Portal vein thrombosis 
 No 247 (72.2)
 Yes 95 (28.8)
Treatment 
 None 183 (53.5)
 Surgery 52 (15.2)
 TACE 105 (30.7)
 PEIT 41 (12.1)
HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; TACE = 
transcatheter arterial chemoembolization; PEIT = percutaneous ethanol 
injection.
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factors [9–13,17–22]. New staging systems for HCC 
have been developed, including the CLIP (from Italy), 
the Barcelona Clinic Liver Cancer system (BCLC, Spain) 
[10], the French classification [11], the Chinese Uni-
versity Prognostic Index (CUPI, Hong Kong) [12] and 
the Japan Integrated Score (JIS, Japan) [23]. Each has 
been shown to have predictive power for HCC. These 
systems share common features of combined assess-
ment of tumor burden with markers of liver function 
and the addition of many factors that are probably re-
lated to the survival time. The residual liver function at 
the time of diagnosis of HCC has been increasingly 
emphasized by most investigators. This was also con-
firmed by our study, demonstrating that the Child-Pugh 
classification can also predict the outcome of patients 
with HCC. However, the BCLC and French systems in-
clude subjective parameters, such as performance sta-
tus, which increase interpersonal bias and are difficult 
to assess in a retrospective fashion. The CUPI and JIS 
systems include the TNM status, which is complicated, 
and the exact estimation can be impossible in patients 
who have not received surgical intervention [13,17].
The CLIP system, originally proposed by the Cancer 
of the Liver Italian Program, includes tumor character-
istics, vascular invasion, and liver function reserve. It 
has been shown to have high discriminatory power in 
many retrospective studies [18–20]. Moreover, pro-
spective studies have shown that CLIP is suitable for 
Table 3 — Survival of hepatocellular carcinoma patients according to CLIP or Okuda classifications
 
n (%)
 Median survival in Survival rate (%) p of log-
  months (95% CI) 6 mo 1 yr 3 yr 5 yr rank test
CLIP score       < 0.0001
 0 35 (10.2) 32.736 (11.934–44.669) 0.714 0.657 0.486 0.229
 1 55 (16.1) 10.298 (6.802–16.901) 0.673 0.473 0.236 0.139
 2 79 (23.1) 6.736 (4.504–10.628) 0.532 0.367 0.139 0.100
 3 85 (24.9) 4.727 (3.066–6.628) 0.435 0.247 0.059 0.011
 4 52 (15.2) 2.450 (1.769–3.496) 0.192 0.096 0.039 0.000
 5 27 (7.9) 1.934 (1.231–2.471) 0.185 0.111 0.037 0.000
 6 9 (2.6) 0.835 (0.331–1.562) 0.000 0.000 0.000 0.000
Okuda stage       < 0.0001
 I  83 (24.3) 16.802 (10.298–27.231) 0.699 0.578 0.325 0.188
 II 192 (56.1) 4.967 (4.099–6.397) 0.453 0.271 0.104 0.052
 III 67 (19.6) 1.934 (1.207–2.231) 0.164 0.105 0.030 0.000
Child-Pugh       < 0.0001
 A 144 (42.1) 8.603 (6.397–10.298) 0.611 0.396 0.215 0.131
 B 139 (40.6) 3.430 (2.636–5.000) 0.396 0.302 0.115 0.050
 C 59 (17.3) 1.934 (1.231–2.760) 0.220 0.136 0.034 0.000
Overall 342 (100) 4.760 (4.000–6.132) 0.456 0.313 0.143 0.074
CI = confidence interval; CLIP = Cancer of the Liver Italian Program.
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Fig. 1 — Survival curves of patients plotted using the Kaplan-Meier method according to Cancer of the Liver Italian 
Program (CLIP) scores.
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Fig. 2 — Survival curves of patients plotted using the Kaplan-Meier method according to the Okuda stages.
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Fig. 3 — Survival probability curves of patients plotted 
using Cox’s proportional hazards regression method 
according to Cancer of the Liver Italian Program (CLIP) 
scores, merging scores 4, 5 and 6.
Table 4 — Survival prediction of hepatocellular carcinoma 
patients according to CLIP or Okuda classifications 
analyzed by Cox’s proportional hazards regression
 Regression 
SE p RR 95% CI
 coefficient
CLIP 0.4358 0.04815 0.0000 1.5462 1.4077–1.6985
Okuda 0.7083 0.08974 0.0000 2.0305 1.7046–2.4189
CLIP = Cancer of the Liver Italian Program, merging scores 4, 5 and 6; 
SE = standard error; RR = relative risk; CI = confidence interval.
Table 5 — Comparison of the prognostic stratification* 
of CLIP and Okuda classifications
  Homogeneity  Akaike’s 
 Linear trend χ2 likelihood  information 
  ratio test criterion
CLIP 77.0076 87.2844 3163.74749
Okuda 59.8840 62.0593 3188.97259
*Higher values of discriminatory ability linear trend χ2 test and 
homogeneity likelihood ratio χ2 test and lower value of Akaike’s 
information criterion were associated with better prognostic strati-
fication of the system. CLIP = Cancer of the Liver Italian Program, 
merging scores 4, 5 and 6.
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Fig. 4 — Survival probability curves of patients plotted 
using Cox’s proportional hazards regression method 
according to the Okuda stages.
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identifying the prognosis of patients after surgery [23] 
and transcatheter arterial chemoembolization [24]. 
A modified CLIP score using protein induced by vitamin 
K antagonist II (PIVKA-II), as proposed by Nanashima 
et al, showed a better discrimination ability for pa-
tient survival [23], but this marker is not universally 
available or accepted.
Although only a fraction of patients in our study had 
pathologically proven HCC, most of our patients had 
typical clinical presentations, compatible imaging find-
ings and elevated AFP levels. The apparently poorer 
outcomes of our patients probably occurred because 
we included many patients who died soon after diagno-
sis, which may be due to inefficient cancer screening 
efforts and policies. In addition, because percutane-
ous ethanol injection therapy and radiofrequency ab-
lation can be performed on an outpatient basis [4,5], 
many patients with smaller tumors were not included 
in this chart review of inpatients.
The results of our study showed accuracy and predic-
tive power of the CLIP system which were comparable 
with previous retrospective studies [9,18,19]. The 
CLIP prognosis prediction system can be used to 
stratify patients diagnosed with HCC in eastern 
Taiwan for prospective therapeutic trials.
References
 1. Department of Health, Taiwan, ROC. Analysis of Main 
Causes of Death in Taiwan for the Year 2002. Available at: 
www.doh.gov.tw/dohenglish/Upload/Statistics/S02/
Analysis%20of%20Main%20Causes%20of%20Death%20
in%20Taiwan%20for%20the%20Year%202002-eng-rev.
doc [Date accessed: January 2004]
 2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic 
view. J Clin Gastroenterol 2002;35(5 Suppl 2):S72–8.
 3. Koteish A, Thuluvath PJ. Screening for hepatocellular 
carcinoma. J Vasc Interv Radiol 2002;13:S185–90.
 4. Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Review 
article: percutaneous treatment of hepatocellular carci-
noma. Aliment Pharmacol Ther 2003;17(Suppl 2):103–10.
 5. Lin SM, Lin DY. Percutaneous local ablation therapy in 
small hepatocellular carcinoma. Chang Gung Med J 2003;
26:308–14.
 6. Gholson CF, Provenza JM, Bacon BR. Hepatologic consid-
erations in patients with parenchymal liver disease under-
going surgery. Am J Gastroenterol 1990;85:487–96.
 7. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma 
in the United States. Prognostic features, treatment out-
come, and survival. Cancer 1996;77:2217–22.
 8. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepa-
tocellular carcinoma and prognosis in relation to treatment: 
study of 850 patients. Cancer 1985;56:918–28.
 9. The Cancer of the Liver Italian Program (CLIP) investigators. 
A new prognostic system for hepatocellular carcinoma: a 
retrospective study of 435 patients. Hepatology 1998;28:
751–5.
10. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular car-
cinoma: the BCLC staging classification. Semin Liver Dis 
1999;19:329–38.
11. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, 
Chastang C. A new prognostic classification for predicting 
survival in patients with hepatocellular carcinoma. Group 
d’Etude et de traitement du carcinoma hepatocellulaire. 
J Hepatol 1999;31:133–41.
12. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese 
University Prognostic Index for hepatocellular carcinoma 
and comparison with the TNM staging system, the Okuda 
staging system, and the Cancer of the Liver Italian Program 
staging system: a study based on 926 patients. Cancer 
2002;94:1760–9.
13. The Cancer of the Liver Italian Program (CLIP) investigators. 
Prospective validation of the CLIP score: a new prognostic 
system for patients with cirrhosis and hepatocellular car-
cinoma. Hepatology 2000;31:840–5.
14. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A com-
parison of goodness-of-fit tests for the logistic regression 
model. Stat Med 1997;16:965–80.
15. Feinsten AR. Clinical biostatistics XVI. The process of prog-
nostic stratification. Clin Pharmacol Ther 1972;13:609–24.
16. Foster MR. Key concepts in model selection: performance 
and generalizability. J Math Psychol 2000;44:205–31.
17. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the patho-
logic TMN staging system for patients with hepatoma predic-
tive of outcome? Cancer 2000;88:538–43.
18. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the 
new western prognostic system (CLIP score) for hepatocel-
lular carcinoma in 662 Japanese patients. Cancer of the 
Liver Italian Program. Hepatology 2001;34:529–34.
19. Levy I, Sherman M. Staging of hepatocellular carcinoma: 
assessment of the CLIP, Okuda, and Child-Pugh staging 
systems in a cohort of 257 patients in Toronto. Gut 2002;
50:881–5.
20. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should 
patients with hepatocellular carcinoma be staged? Valida-
tion of a new prognostic system. Cancer 2000;89:2266–73.
21. Rose AT, Rose DM, Pinson CW, et al. Hepatocellular carci-
noma outcomes based on indicated treatment strategy. 
Am Surg 1998;64:1128–35.
22. Chen JC, Chen CC, Chen WJ, Lai HS, Hung WT, Lee PH. 
Hepatocellular carcinoma in children: clinical review and 
comparison with adult cases. J Pediatr Surg 1998;33:
1350–4.
23. Nanashima A, Omagari K, Tobinaga S, et al. Comparative 
study of survival of patients with hepatocellular carci-
noma predicted by different staging systems using multi-
variate analysis. Eur J Surg Oncol 2005;31:882–90.
24. Biselli M, Andreone P, Gramenzi A, et al. Transcatheter arte-
rial chemoembolization therapy for patients with hepatocel-
lular carcinoma: a case-controlled study. Clin Gastroenterol 
Hepatol 2005;3:918–25.
